Luminex Corporation
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. The company was founded in 1995 and is based in Austin, Texas. It has additional offices in Northbrook, Illinois; Madison, Wisconsin; Seattle, Washington; ‘s-Hertogenbosch, the Netherlands; Shanghai, China; Kowloon, Hong Kong; Tokyo, Japan; and Toronto, Canada. As of July 14, 2021, Luminex Corporation operates as a subsidiary of DiaSorin S.p.A.
Market Cap
$1.8B
Volume
684.1K
Cash and Equivalents
$271.6M
EBITDA
$85.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$264.0M
Profit Margin
60.31%
52 Week High
$41.69
52 Week Low
$20.61
Dividend
N/A
Price / Book Value
3.51
Price / Earnings
73.89
Price / Tangible Book Value
5.93
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$54.7M
Return on Equity
4.97%
Return on Assets
5.06
Cash and Short Term Investments
$271.6M
Debt
$274.9M
Equity
$488.0M
Revenue
$437.7M
Unlevered FCF
$5.1M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium